These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
598 related articles for article (PubMed ID: 30340359)
1. The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma. García-Reyes B; Kretz AL; Ruff JP; von Karstedt S; Hillenbrand A; Knippschild U; Henne-Bruns D; Lemke J Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30340359 [TBL] [Abstract][Full Text] [Related]
2. The roles and therapeutic potential of cyclin-dependent kinases (CDKs) in sarcoma. Liao Y; Feng Y; Shen J; Hornicek FJ; Duan Z Cancer Metastasis Rev; 2016 Jun; 35(2):151-63. PubMed ID: 26669603 [TBL] [Abstract][Full Text] [Related]
3. THZ1 reveals CDK7-dependent transcriptional addictions in pancreatic cancer. Lu P; Geng J; Zhang L; Wang Y; Niu N; Fang Y; Liu F; Shi J; Zhang ZG; Sun YW; Wang LW; Tang Y; Xue J Oncogene; 2019 May; 38(20):3932-3945. PubMed ID: 30692639 [TBL] [Abstract][Full Text] [Related]
4. Induction of cell death in pancreatic ductal adenocarcinoma by indirubin 3'-oxime and 5-methoxyindirubin 3'-oxime in vitro and in vivo. Sano M; Ichimaru Y; Kurita M; Hayashi E; Homma T; Saito H; Masuda S; Nemoto N; Hemmi A; Suzuki T; Miyairi S; Hao H Cancer Lett; 2017 Jul; 397():72-82. PubMed ID: 28347789 [TBL] [Abstract][Full Text] [Related]
5. Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers. Santo L; Siu KT; Raje N Semin Oncol; 2015 Dec; 42(6):788-800. PubMed ID: 26615126 [TBL] [Abstract][Full Text] [Related]
6. Cyclin-dependent kinase inhibition: an opportunity to target protein-protein interactions. Klein MA Adv Protein Chem Struct Biol; 2020; 121():115-141. PubMed ID: 32312419 [TBL] [Abstract][Full Text] [Related]
7. The inhibition of cell proliferation and induction of apoptosis in pancreatic ductal adenocarcinoma cells by verrucarin A, a macrocyclic trichothecene, is associated with the inhibition of Akt/NF-кB/mTOR prosurvival signaling. Deeb D; Gao X; Liu Y; Zhang Y; Shaw J; Valeriote FA; Gautam SC Int J Oncol; 2016 Sep; 49(3):1139-47. PubMed ID: 27573873 [TBL] [Abstract][Full Text] [Related]
8. The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer. Ding L; Cao J; Lin W; Chen H; Xiong X; Ao H; Yu M; Lin J; Cui Q Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183020 [TBL] [Abstract][Full Text] [Related]
9. The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma. Fu Y; Liu S; Zeng S; Shen H Mol Cancer; 2018 Feb; 17(1):62. PubMed ID: 29458370 [TBL] [Abstract][Full Text] [Related]
10. Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines. Ma Y; Sender S; Sekora A; Kong W; Bauer P; Ameziane N; Krake S; Radefeldt M; Al-Ali R; Weiss FU; Lerch MM; Parveen A; Zechner D; Junghanss C; Murua Escobar H Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457227 [TBL] [Abstract][Full Text] [Related]
11. Concepts to Target MYC in Pancreatic Cancer. Wirth M; Mahboobi S; Krämer OH; Schneider G Mol Cancer Ther; 2016 Aug; 15(8):1792-8. PubMed ID: 27406986 [TBL] [Abstract][Full Text] [Related]
12. Efemp1 and p27(Kip1) modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models. Diersch S; Wenzel P; Szameitat M; Eser P; Paul MC; Seidler B; Eser S; Messer M; Reichert M; Pagel P; Esposito I; Schmid RM; Saur D; Schneider G Oncotarget; 2013 Feb; 4(2):277-88. PubMed ID: 23470560 [TBL] [Abstract][Full Text] [Related]
13. Cell cycle plasticity driven by MTOR signaling: integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer. Knudsen ES; Kumarasamy V; Ruiz A; Sivinski J; Chung S; Grant A; Vail P; Chauhan SS; Jie T; Riall TS; Witkiewicz AK Oncogene; 2019 May; 38(18):3355-3370. PubMed ID: 30696953 [TBL] [Abstract][Full Text] [Related]
14. FAK and paxillin, two potential targets in pancreatic cancer. Kanteti R; Batra SK; Lennon FE; Salgia R Oncotarget; 2016 May; 7(21):31586-601. PubMed ID: 26980710 [TBL] [Abstract][Full Text] [Related]
15. NF45 overexpression is associated with poor prognosis and enhanced cell proliferation of pancreatic ductal adenocarcinoma. Wan C; Gong C; Ji L; Liu X; Wang Y; Wang L; Shao M; Yang L; Fan S; Xiao Y; Wang X; Li M; Zhou G; Zhang Y Mol Cell Biochem; 2015 Dec; 410(1-2):25-35. PubMed ID: 26276310 [TBL] [Abstract][Full Text] [Related]
16. Dissecting the Pol II transcription cycle and derailing cancer with CDK inhibitors. Parua PK; Fisher RP Nat Chem Biol; 2020 Jul; 16(7):716-724. PubMed ID: 32572259 [TBL] [Abstract][Full Text] [Related]
17. Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy. Chou J; Quigley DA; Robinson TM; Feng FY; Ashworth A Cancer Discov; 2020 Mar; 10(3):351-370. PubMed ID: 32071145 [TBL] [Abstract][Full Text] [Related]
19. The CCR5 antagonist maraviroc causes remission of pancreatic cancer liver metastasis in nude rats based on cell cycle inhibition and apoptosis induction. Huang H; Zepp M; Georges RB; Jarahian M; Kazemi M; Eyol E; Berger MR Cancer Lett; 2020 Apr; 474():82-93. PubMed ID: 31954769 [TBL] [Abstract][Full Text] [Related]
20. Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions. Zhang Y; Yang C; Cheng H; Fan Z; Huang Q; Lu Y; Fan K; Luo G; Jin K; Wang Z; Liu C; Yu X J Hematol Oncol; 2018 Jan; 11(1):14. PubMed ID: 29386069 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]